SAGE THERAPEUTICS INC (SAGE)
US78667J1088 - Common Stock
SAGE gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. SAGE has a great financial health rating, but its profitability evaluates not so good. SAGE is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SAGE has reported negative net income.
SAGE had a negative operating cash flow in the past year.
In the past 5 years SAGE reported 4 times negative net income.
In the past 5 years SAGE reported 4 times negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -65.54%, SAGE perfoms like the industry average, outperforming 40.07% of the companies in the same industry.
SAGE's Return On Equity of -71.28% is in line compared to the rest of the industry. SAGE outperforms 58.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.54% | ||
| ROE | -71.28% | ||
| ROIC | N/A |
ROA(3y)-41.91%
ROA(5y)-32.08%
ROE(3y)-45.58%
ROE(5y)-35.9%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SAGE's Gross Margin of 96.50% is amongst the best of the industry. SAGE outperforms 97.77% of its industry peers.
SAGE's Gross Margin has been stable in the last couple of years.
SAGE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.82%
GM growth 5YN/A
2. Health
2.1 Basic Checks
SAGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SAGE has been increased compared to 1 year ago.
The number of shares outstanding for SAGE has been increased compared to 5 years ago.
SAGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 2.12 indicates that SAGE is not a great score, but indicates only limited risk for bankruptcy at the moment.
SAGE has a better Altman-Z score (2.12) than 65.75% of its industry peers.
SAGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.12 |
ROIC/WACCN/A
WACC9.34%
2.3 Liquidity
A Current Ratio of 12.22 indicates that SAGE has no problem at all paying its short term obligations.
SAGE has a Current ratio of 12.22. This is amongst the best in the industry. SAGE outperforms 81.51% of its industry peers.
SAGE has a Quick Ratio of 12.22. This indicates that SAGE is financially healthy and has no problem in meeting its short term obligations.
SAGE's Quick ratio of 12.22 is amongst the best of the industry. SAGE outperforms 81.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 12.22 | ||
| Quick Ratio | 12.22 |
3. Growth
3.1 Past
The earnings per share for SAGE have decreased by -2.99% in the last year.
Looking at the last year, SAGE shows a very strong growth in Revenue. The Revenue has grown by 868.87%.
Measured over the past years, SAGE shows a decrease in Revenue. The Revenue has been decreasing by -0.87% on average per year.
EPS 1Y (TTM)-2.99%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q26.83%
Revenue 1Y (TTM)868.87%
Revenue growth 3Y-57.35%
Revenue growth 5Y-0.87%
Revenue growth Q2Q139.45%
3.2 Future
The Earnings Per Share is expected to grow by 20.35% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 58.58% on average over the next years. This is a very strong growth
EPS Next Y38.26%
EPS Next 2Y24.01%
EPS Next 3Y19.1%
EPS Next 5Y20.35%
Revenue Next Year-46.61%
Revenue Next 2Y39.3%
Revenue Next 3Y67.07%
Revenue Next 5Y58.58%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SAGE. In the last year negative earnings were reported.
Also next year SAGE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SAGE's earnings are expected to grow with 19.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.01%
EPS Next 3Y19.1%
5. Dividend
5.1 Amount
No dividends for SAGE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SAGE THERAPEUTICS INC
NASDAQ:SAGE (4/26/2024, 7:14:54 PM)
After market: 13.69 0 (0%)13.69
+0.11 (+0.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap822.91M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.54% | ||
| ROE | -71.28% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.5% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 12.22 | ||
| Quick Ratio | 12.22 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-2.99%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y38.26%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)868.87%
Revenue growth 3Y-57.35%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y